Prenetics, a Hong Kong DNA biotechnology firm, raised $10 million in a Series A funding led by China’s Ping An Ventures. Prenetics is developing the iGenes test that makes pharmacogenomics available in the clinic. Based on an individual’s genome, the test identifies the best medicine for a particular disease, avoids those that would cause an adverse reaction, and guides dosing levels. The test, according to Prenetics, avoids the “trial and error” method of prescribing medicines.
